Axa
BPMC

Axa’s Blueprint Medicines BPMC Stock Holding History

Axa’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-89,521
Closed -$9.59M – 1186
2021
Q4 		$9.59M Sell
89,521
-20,700
-19% -$2.17M 0.02% 502
2021
Q3 		$11.3M Buy
110,221
+12,328
+13% +$1.15M 0.03% 461
2021
Q2 		$8.61M Sell
97,893
-7,438
-7% -$682K 0.02% 555
2021
Q1 		$10.2M Buy
105,331
+1,958
+2% +$195K 0.03% 511
2020
Q4 		$11.6M Buy
103,373
+2,900
+3% +$306K 0.04% 474
2020
Q3 		$9.31M Sell
100,473
-992
-1% -$76.4K 0.03% 478
2020
Q2 		$7.91M Buy
101,465
+45,847
+82% +$3.1M 0.03% 495
2020
Q1 		$3.25M Buy
+55,618
New +$3.58M 0.02% 631
2019
Q4 		– Sell
-107,575
Closed -$7.9M – 1179
2019
Q3 		$7.9M Sell
107,575
-161
-0.1% -$13.9K 0.03% 534
2019
Q2 		$10.2M Sell
107,736
-18,054
-14% -$1.49M 0.04% 472
2019
Q1 		$10.1M Buy
125,790
+95,386
+314% +$7.05M 0.04% 457
2018
Q4 		$1.64M Hold
30,404
– – 0.01% 863
2018
Q3 		$2.37M Sell
30,404
-8,500
-22% -$591K 0.01% 842
2018
Q2 		$2.47M Buy
38,904
+27,604
+244% +$2.2M 0.01% 805
2018
Q1 		$1.04M Sell
11,300
-1,500
-12% -$129K ﹤0.01% 995
2017
Q4 		$965K Buy
12,800
+3,300
+35% +$232K ﹤0.01% 1009
2017
Q3 		$662K Buy
+9,500
New +$508K ﹤0.01% 1054

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Axa's BPMC Position: Q1 2022 in Review

Axa sold out of Blueprint Medicines (BPMC) in Q1 2022, closing a stake of 89,521 shares — an estimated $9.59M sold.

Axa first reported a position in BPMC in Q3 2017 and held it in 17 quarters. The position peaked at $11.6M in Q4 2020. 248 funds tracked by Wall St. Rank hold BPMC as of Q1 2022.

  • Axa reported no remaining Blueprint Medicines position as of Q1 2022 after selling out during the quarter.
  • Axa sold 89,521 Blueprint Medicines shares in Q1 2022, an estimated $9.59M.
  • Axa first reported a position in Blueprint Medicines in Q3 2017 and held it in 17 quarters.
  • Axa's Blueprint Medicines position peaked at $11.6M in Q4 2020.
  • 248 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2022.

Based on Axa's 13F filing for Q1 2022, filed 13 May 2022.